If you or a loved one are concerned about the risk of progressive multifocal leukoencephalopathy (PML) while taking Tysabri, understanding the timeline of onset and FDA safety monitoring can help you make informed decisions. Building on decades of pharmacovigilance research, this page reviews the evidence on PML risk factors, symptom progression, and recommended follow-up windows.
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in North Carolina who have developed PML after Tysabri treatment, understanding the medical evidence linking the drug to this harm, as well as the legal context of settlements and statutes of limitations, is critical. The FDA-approved prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical data and postmarketing surveillance. Three specific risk factors for PML have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing Tysabri therapy. The clinical presentation of PML is variable but typically includes progressive neurological deficits such as weakness, visual disturbances, cognitive decline, and coordination problems. Diagnosis is confirmed by brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The disease is often fatal, and survivors frequently experience severe disability. The prescribing information emphasizes that healthcare professionals should "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri prevents immune cells from crossing the blood-brain barrier, which reduces inflammation in the central nervous system but also impairs normal immune surveillance. This allows the JC virus, which is latent in many individuals, to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The risk is highest in patients who are seropositive for anti-JCV antibodies, as this indicates prior exposure to the virus. Regarding the adequacy of warnings, the boxed warning and the TOUCH Prescribing Program are designed to inform patients and prescribers of the PML risk. The TOUCH program requires that patients be enrolled, read a Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, some patients and their families have alleged that these warnings were insufficient or that the risk was not adequately communicated, leading to claims for compensation.
For affected patients in North Carolina, settlement-related considerations often involve the timeline between Tysabri exposure and documented harm. PML typically develops after months to years of treatment, with the risk increasing after two years. The statute of limitations for filing a product liability lawsuit in North Carolina is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. This means that patients diagnosed with PML must act promptly to preserve their legal rights. Settlement amounts in Tysabri PML cases have varied widely, depending on factors such as the severity of disability, medical expenses, lost income, and the strength of evidence regarding inadequate warnings. In summary, the medical evidence clearly establishes that Tysabri increases the risk of PML, a devastating disease. Patients in North Carolina who have suffered this harm should be aware of the risk factors, the importance of early diagnosis, and the legal time limits for seeking compensation. Consulting with an attorney experienced in pharmaceutical litigation is advisable to navigate the statute of limitations and settlement process. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962)
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In North Carolina, the statute of limitations for filing a product liability lawsuit is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered. For Tysabri-related PML, this means patients must act promptly after diagnosis to preserve their legal rights.
Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are outlined in the FDA-approved prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.
Request archival records or inquire about member-exclusive transition and benefit programs.